Accentia Biopharmaceuticals Report issue

For profit Phase 2 Phase 3
Founded: Tampa FL United States (2002)
Status: Defunct (2013)

Organization Overview

First Clinical Trial
2006
NCT00425620
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Accentia | Revimmune

Active Ingredients

Drugs in Phase 3 Trials (1)

amphotericin b (fungizone) (1 trial)

Drugs in Phase 2 Trials (2)

cyt107 (4 trials)

il-7 (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Disease (Phase 3)

Lung Diseases (Phase 2)

Lymphopenia (Phase 2)

Mycobacterium Infections (Phase 2)

Mycobacterium Infections, Nontuberculous (Phase 2)

Sepsis (Phase 2)

Sinusitis (Phase 3)

Toxemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 3